SIREN : 682003991
ADECCO MEDICAL is a French company founded 43 years ago, specialized in the sector Activités des agences de travail temporaire . Based in VILLEURBANNE (69100), this company of category GE shows in 2024 a revenue of 238.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238 010 556 € | 265 162 258 € | 230 163 911 € | 180 809 976 € | 141 189 499 € | 123 140 197 € | 110 584 365 € | 93 530 911 € | 81 359 168 € |
| Net income | 2 782 381 € | 8 001 707 € | 8 844 398 € | 5 380 185 € | 2 187 113 € | 1 731 651 € | 2 493 965 € | 265 048 € | -551 459 € |
| EBITDA | 10 918 277 € | 16 224 669 € | 16 336 254 € | 11 269 810 € | 6 153 600 € | 5 217 687 € | 1 437 510 € | 1 750 451 € | -1 273 416 € |
| Net margin | 1.2% | 3.0% | 3.8% | 3.0% | 1.5% | 1.4% | 2.3% | 0.3% | -0.7% |
In 2024, ADECCO MEDICAL achieves revenue of 238.0 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +14.4%. Significant drop of -10% vs 2023. After deducting consumption (0 €), gross margin stands at 238.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 10.9 M€, representing 4.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.8 M€, i.e. 1.2% of revenue. This profit can be retained or distributed to shareholders.
238 010 556 €
238 010 556 €
10 918 277 €
2 527 655 €
2 782 381 €
4.6%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 1.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.239%
42.706%
1.508%
0.024
43.7%
In 2024, the debt ratio of ADECCO MEDICAL (0.24) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of ADECCO MEDICAL (42.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of ADECCO MEDICAL (0.02) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 178.38. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.2x. Operating income very largely covers interest expenses: high safety margin.
178.381
6.157
In 2024, the liquidity ratio of ADECCO MEDICAL (178.38) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of ADECCO MEDICAL (6.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 55 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 91 days. Excellent situation: suppliers finance 36 days of the operating cycle (retail model). Overall, WCR represents 62 days of revenue, i.e. 41.2 M€ to permanently finance. Over 2016-2024, WCR increased by +1735%, requiring additional financing.
41 171 066 €
55 j
91 j
0 j
62 j
Based on 135 transactions of similar company sales (all years), the value of ADECCO MEDICAL is estimated at 17 591 941 € (range 10 133 834€ - 38 578 555€). With an EBITDA of 10 918 277€, the sector multiple of 2.0x is applied. The price/revenue ratio is 0.08x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 135 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ADECCO MEDICAL with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des agences de travail temporaire
The revenue of ADECCO MEDICAL in 2024 is 238.0 M€.
Yes, ADECCO MEDICAL generated a net profit of 2.8 M€ in 2024.
The headquarters of ADECCO MEDICAL is located in VILLEURBANNE (69100), in the department Rhone.
The tax return of ADECCO MEDICAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ADECCO MEDICAL operates in the sector Activités des agences de travail temporaire (NAF code 78.20Z). See the 'Sector positioning' section above to compare the company with its competitors.